Search: JOTROL — Incisor News

BREAKING

Global markets surge as central banks signal pause on interest rate hikes AI breakthrough: New model achieves human-level reasoning across all domains World leaders convene emergency climate summit amid record-breaking temperatures

LIVE MARKETS

US📈 S&P 500$5,738.17▲ 0.41% METAL🥇 GOLD$2,658.40/oz▲ 0.52% ENERGY🛢️ BRENT$71.89/bbl▲ 0.68% CRYPTO₿ BTC$65,840.00▲ 1.85% IN🇮🇳 NIFTY 50₹26,178.95▲ 0.30% METAL🥈 SILVER$31.62/oz▲ 1.18% US💻 NASDAQ$18,179.59▲ 0.60% ENERGY🛢️ WTI CRUDE$68.18/bbl▲ 0.75% CRYPTOΞ ETH$2,664.20▲ 2.10% IN🇮🇳 SENSEX₹85,571.85▲ 0.28% US🏛️ DOW$42,313.00▲ 0.33% CRYPTO◎ SOL$156.40▲ 4.30% UK🇬🇧 FTSE 100£8,320.72▲ 0.43% CRYPTO⬡ BNB$598.20▲ 0.85% US📈 S&P 500$5,738.17▲ 0.41% METAL🥇 GOLD$2,658.40/oz▲ 0.52% ENERGY🛢️ BRENT$71.89/bbl▲ 0.68% CRYPTO₿ BTC$65,840.00▲ 1.85% IN🇮🇳 NIFTY 50₹26,178.95▲ 0.30% METAL🥈 SILVER$31.62/oz▲ 1.18% US💻 NASDAQ$18,179.59▲ 0.60% ENERGY🛢️ WTI CRUDE$68.18/bbl▲ 0.75% CRYPTOΞ ETH$2,664.20▲ 2.10% IN🇮🇳 SENSEX₹85,571.85▲ 0.28% US🏛️ DOW$42,313.00▲ 0.33% CRYPTO◎ SOL$156.40▲ 4.30% UK🇬🇧 FTSE 100£8,320.72▲ 0.43% CRYPTO⬡ BNB$598.20▲ 0.85%

Markets

Business Oct 7, 2026 1 min read

Jupiter Neurosciences Doses First Patient in Phase 2a RESET Trial for Parkinson’s Disease, Explores Strategic Options

Jupiter Neurosciences has dosed the first patient in its Phase 2a RESET trial of JOTROL™ for Parkinson’s disease, evaluating safety, pharmacokinetics, and biomarkers. Concurrently, the company is expl…

Staff 1 views Read Article

Search Results for "JOTROL"